Toward a Comprehensive Measure of Drug-Attributable Harm

JAMA. 2024 Aug 13;332(6):455-456. doi: 10.1001/jama.2024.9642.
No abstract available

Plain language summary

This Viewpoint from authors at the Harvard T.H. Chan School of Public Health summarizes approaches to addressing substance use in the US; challenges posed by metrics such as overdose deaths; and more informative metrics, such as quality-adjusted life-years, to promote health equity and improve length and quality of life and health outcomes at all levels.

MeSH terms

  • Chronic Disease
  • Disability-Adjusted Life Years*
  • Drug Overdose / mortality
  • Drug-Related Side Effects and Adverse Reactions* / epidemiology
  • Global Burden of Disease
  • Humans
  • Substance-Related Disorders* / epidemiology
  • United States / epidemiology